However, at the level of the individual MPN patient, Zeuner et al. did not detect a strict correlation between Bcl-2 or Bcl-xL expression and drug resistance, indicating that response to therapy may be determined by additional underlying anti-apoptosis mechanisms. Here, BCL2L1 is linked to myeloproliferative disorder.